Brazil approves first generic semaglutide pen after Ozempic patent expiry
SAO PAULO, May 26 (Reuters) – Brazil’s health regulator Anvisa said on Tuesday it had approved EMS’s Ozivy, the country’s first semaglutide-based injector pen, as the drugmaker looks to expand into a higher-end segment of the global pharmaceutical industry. The drug uses the same active ingredient as Novo Nordisk’s diabetes and weight-loss drug Ozempic, whose patent expired in Brazil in March. • Drug to be produced at EMS plant in […]